ZURA Stock Analysis: Zura Bio Ordinary Shares | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 560m USD | 12M Return: 361.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.10M
Warnings
Tailwinds
Seasonality 3.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Zura Bio Limited (NASDAQ: ZURA) is a clinical-stage biotechnology company based in Henderson, Nevada, focused on developing treatments for autoimmune and inflammatory disorders. The companys pipeline includes three therapeutic candidates: Tibulizumab, a bispecific antibody targeting IL-17A and BAFF currently in Phase 2 trials; Torudokimab (ZB-880), a monoclonal antibody against IL-33 that has completed Phase 1 studies; and Crebankitug (ZB-168), a monoclonal antibody targeting the IL-7 receptor alpha, also having completed Phase 1 studies.
As a clinical-stage biotechnology company, Zura Bio has no approved products on the market and relies on capital markets to fund its research and development activities. The companys pipeline targets cytokine pathways (IL-17A, BAFF, IL-33, and IL-7Rα) that play established roles in immune system regulation, placing it within a competitive segment of the biopharmaceutical industry where many larger pharmaceutical companies are also active.
- Phase 2 Tibulizumab data readout in autoimmune indications
- Cash runway concerns raise potential share dilution risk
- Torudokimab and Crebankitug advance to next clinical phase
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA -11.95 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.32 > 3% & CFO -72.7m > Net Income -75.4m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 19.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.2m) vs 12m ago 71.86% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.00%; Δ -0.00% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 227.0m - Total Current Liabilities 11.7m) / Total Assets 228.6m |
| B: -1.09 (Retained Earnings -248.8m / Total Assets 228.6m) |
| C: -0.38 (EBIT TTM -75.4m / Avg Total Assets 200.6m) |
| D: 18.47 (Book Value of Equity 216.9m / Total Liabilities 11.7m) |
| Altman-Z'' = 19.49 = AAA |
As of July 08, 2026, the stock is trading at USD 5.08 with a total of 1,261,288 shares traded. Over the past week, the price has changed by -9.77%, over one month by +43.91%, over three months by -10.09% and over the past year by +361.82%.
Current recommended Stop Loss: 4.10 (which is 19.3% or 2.3 ATR below the current price).
Zura Bio Ordinary Shares has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy ZURA.
- StrongBuy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.7 | 208.5% |
P/B = 2.5809
Revenue TTM = 0.0 USD
EBIT TTM = -75.4m USD
EBITDA TTM = -75.4m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 334.2m USD (559.8m + (null Debt) - CCE 225.6m)
Interest Coverage Ratio = unknown (Ebit TTM -75.4m / Interest Expense TTM 0.0)
EV/FCF = -4.59x (Enterprise Value 334.2m / FCF TTM -72.8m)
FCF Yield = -21.77% (FCF TTM -72.8m / Enterprise Value 334.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 56.0k) / Revenue TTM)
Tobins Q-Ratio = 1.46 (Enterprise Value 334.2m / Total Assets 228.6m)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -59.6m (EBIT -75.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 19.33 (Total Current Assets 227.0m / Total Current Liabilities 11.7m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -75.4m)
Debt / FCF = unknown (Net Debt none / FCF TTM -72.8m)
Total Stockholder Equity = 138.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.61% (Net Income -75.4m / Total Assets 228.6m)
RoE = -54.60% (Net Income TTM -75.4m / Total Stockholder Equity 138.1m)
RoCE = -34.78% (EBIT -75.4m / Capital Employed (Total Assets 228.6m - Current Liab 11.7m))
RoIC = -27.47% (negative operating profit) (NOPAT -59.6m / Invested Capital 216.9m)
WACC = 11.18% (E(559.8m)/V(559.8m) * Re(11.18%) + (debt-free company))
Discount Rate = 11.18% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 67.42 | Cagr: 47.16%
[DCF] Fair Price = unknown (Cash Flow -72.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.22 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.10 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.10 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.44 | Chg30d=+25.42% | Revisions=+25% | GrowthEPS=+58.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.10 | Chg30d=+28.57% | Revisions=+25% | GrowthEPS=+77.3% | GrowthRev=+0.0%